Comprehensive Genomic Profiling (CGP) in the U.S. - Medical Oncologist, Southwest Community Hospital

A medical oncologist discusses their perceptions of CGP and its importance in patient care. They highlight the need for obtaining information on a wide range of genes and actionable mutations, with an emphasis on the importance RNA coverage for fusion genes. They also note the limitations of clinical trial matching support and the frustrations experienced by pathologists in implementing CGP testing, emphasizing the lack of integration into electronic medical record systems. The stakeholder notes the value of CGP in guiding treatment decisions, particularly in breast and colorectal cancer patients. When discussing CGP testing vendors, they mention their top choices and preference for tissue-based testing. The stakeholder highlights cost as a significant factor in choosing CGP assay vendors and mentions the importance of one vendor for both CGP testing and MRD testing for solid tumors. They also discuss their experience with CGP in breast cancer patients and the increasing use of CGP due to recent approvals for specific mutations.

‍